Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Oncimmune Inks Chinese Licensing Deal for Diagnostics Platform

Jan 03, 2018
|
staff reporter

NEW YORK (360Dx) – Cancer detection firm Oncimmune announced on Tuesday that it has signed a licensing agreement for its EarlyCDT autoantibody-based diagnostics platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

What's Popular?

In Cancer

  1. Roche Elecsys Anti-p53 Test for Cancer Diagnosis Earns CE Mark

  2. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  3. Abcam, MEDx Expand Cancer Diagnostics Development Alliance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.